Evidence map›Paper›PMID 23187941›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2013

Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis.

Amy C Justice, Sharada P Modur, Janet P Tate, Keri N Althoff, Lisa P Jacobson, Kelly A Gebo, Mari M Kitahata, Michael A Horberg, John T Brooks, Kate Buchacz and 19 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Amy C JusticeDepartment of Internal Medicine, Yale University and the Veterans Affairs Healthcare System, West Haven, CT 06516, USA. amy.justice2@va.gov
Sharada P Modur
Janet P Tate
Keri N Althoff
Lisa P Jacobson
Kelly A Gebo
Mari M Kitahata
Michael A Horberg
John T Brooks
Kate Buchacz
Sean B Rourke
Anita Rachlis
Sonia Napravnik
Joseph Eron
James H Willig
Richard Moore
Gregory D Kirk
Ronald Bosch
Benigno Rodriguez
Robert S Hogg
Jennifer Thorne
James J Goedert
Marina Klein
John Gill
Steven Deeks
Timothy R Sterling
Kathryn Anastos
Stephen J Gange
NA-ACCORD and VACS Project Teams

Funding

WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
NATURAL HISTORY OF AIDS IN HOMOSEXUAL MENU01AI035040 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DETELS, ROGER, MARTINEZ-MAZA, OTONIEL · 1993 to 2018
$75.2M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
CIHR 169621CIHR CBR-86906CIHR CBR-94036CIHR HCP-97105CIHR KRS-86251CIHR TGF-96118Intramural NIH HHS Z01 CP010176Intramural NIH HHS ZIA CP010214NCI NIH HHS N02 CP055504NCRR NIH HHS 5-MO1-RR-00052NCRR NIH HHS M01 RR000052NCRR NIH HHS RR025747NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1-RR024131NCRR NIH HHS UL1 RR025747NHLBI NIH HHS HL100347NHLBI NIH HHS R01 HL090342NHLBI NIH HHS R01-HL090342NHLBI NIH HHS R01 HL095136NHLBI NIH HHS R01-HL095136NHLBI NIH HHS RC1 HL100347NIAAA NIH HHS U01 AA013566NIAAA NIH HHS U01-AA013566NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U10 AA013566NIAAA NIH HHS U10-AA13566NIAAA NIH HHS U24 AA022001NIAID NIH HHS AI-69432NIAID NIH HHS AI-69434NIAID NIH HHS K01 AI071725NIAID NIH HHS K01-AI071725NIAID NIH HHS K01 AI071754NIAID NIH HHS K01-AI071754NIAID NIH HHS K01 AI093197NIAID NIH HHS K23-AI-61-0320NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI054999NIAID NIH HHS P30-AI27757NIAID NIH HHS P30-AI27767NIAID NIH HHS P30-AI50410NIAID NIH HHS P30-AI54999NIAID NIH HHS R24 AI067039NIAID NIH HHS R24-AI067039NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI035039NIAID NIH HHS U01 AI035040NIAID NIH HHS U01 AI035041NIAID NIH HHS U01 AI035042NIAID NIH HHS U01 AI035043NIAID NIH HHS U01 AI038855NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069432NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069918NIAID NIH HHS U01-AI069918NIAID NIH HHS U01-AI38855NIAID NIH HHS U01-AI38858NIAID NIH HHS U01-AI68634NIAID NIH HHS U01-AI68636NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069434NIAID NIH HHS UO1-AI-31834NIAID NIH HHS UO1-AI-34989NIAID NIH HHS UO1-AI-34993NIAID NIH HHS UO1-AI-34994NIAID NIH HHS UO1-AI-35004NIAID NIH HHS UO1-AI-35039NIAID NIH HHS UO1-AI-35040NIAID NIH HHS UO1-AI-35041NIAID NIH HHS UO1-AI-35042NIAID NIH HHS UO1-AI-35043NIAID NIH HHS UO1-AI-42590NIA NIH HHS K23 AG024896NIA NIH HHS R01 AG026250NIA NIH HHS R01 AG029154NIA NIH HHS R01-AG029154NICHD NIH HHS U01 HD032632NICHD NIH HHS UO1-HD-32632NIDA NIH HHS R01 DA004334NIDA NIH HHS R01 DA011602NIDA NIH HHS R01 DA012568NIDA NIH HHS R01-DA04334NIDA NIH HHS R01-DA11602NIDA NIH HHS R01-DA12568NIDA NIH HHS U01 DA036297NIEHS NIH HHS T32 ES007069NIEHS NIH HHS T32 ES07069NIMH NIH HHS R01 MH054907NIMH NIH HHS R01-MH54907
6 · The paper itself

Abstract

backgroundBy supplementing an index composed of HIV biomarkers and age (restricted index) with measures of organ injury, the Veterans Aging Cohort Study (VACS) index more completely reflects risk of mortality. We compare the accuracy of the VACS and restricted indices (1) among subjects outside the Veterans Affairs Healthcare System, (2) more than 1-5 years of prior exposure to antiretroviral therapy (ART), and (3) within important patient subgroups.

methodsWe used data from 13 cohorts in the North American AIDS Cohort Collaboration (n = 10, 835) limiting analyses to HIV-infected subjects with at least 12 months exposure to ART. Variables included demographic, laboratory (CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine transaminase, creatinine, and hepatitis C status), and survival. We used C-statistics and net reclassification improvement (NRI) to test discrimination varying prior ART exposure from 1 to 5 years. We then combined Veterans Affairs Healthcare System (n = 5066) and North American AIDS Cohort Collaboration data, fit a parametric survival model, and compared predicted to observed mortality by cohort, gender, age, race, and HIV-1 RNA level.

resultsMean follow-up was 3.3 years (655 deaths). Compared with the restricted index, the VACS index showed greater discrimination (C-statistics: 0.77 vs. 0.74; NRI: 12%; P < 0.0001). NRI was highest among those with HIV-1 RNA <500 copies per milliliter (25%) and age ≥50 years (20%). Predictions were similar to observed mortality among all subgroups.

conclusionsVACS index scores discriminate risk and translate into accurate mortality estimates over 1-5 years of exposure to ART and for diverse patient subgroups from North American.

Indexed as

Age FactorsAlanine TransaminaseAnti-Retroviral AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesCreatinineFemaleHemoglobinsHepatitis CHIV-1HIV InfectionsHumansKaplan-Meier EstimateMaleAlanine TransaminaseAnti-Retroviral AgentsAspartate AminotransferasesBiomarkersCreatinineHemoglobinsRNA, Viral

Identifiers

PMID23187941
PMCPMC3619393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.